Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
Tetra Bio-Pharma (TBP.T) announced today that Health Canada has accepted the Company’s New Drug Submission (NDS) for REDUVO™ and has formally entered the final review phase in the drug review process. Read full article here: https://equity.guru/2021/06/02/tetra-bio-pharmas-tbp-t-reduvo-enters-final-review-with-health-canada-finish-line-in-sight/
